Memorial Sloan Kettering Cancer Center at ASHG 2026
Oct 20–24, 2026Montréal, Canada~7.5k attendeesWebsite
Memorial Sloan Kettering Cancer Center brings 7 presentations from 6 research groups to ASHG 2026 in Montréal. Its program centres on cancer genetics, population-scale sequencing, computational analysis, and clinical translation. Carrot-Zhang Lab brings multi-ancestry sequencing of germline effects on cancer progression, Benjamin Greenbaum Lab brings a body mass index score linked to ovarian cancer survival, and Department of Pathology and Laboratory Medicine brings clonal hematopoiesis findings that can mimic inherited variants.
Develops statistical and machine-learning methods on whole-genome sequencing and linked electronic health-record data. Studies germline effects on tumor evolution, progression and treatment response.
4 papers since 2024
›
Abstract 5222: Multifactorial risks for multiple primary cancers
Cancer Research, 2026
Abstract 3093: SLC25A28 is a synthetic lethal target in nucleotide excision repair-deficient cancer
“We are actively recruiting computational postdocs and graduate students interested in genetic ancestry, germline-somatic interaction and clinical genomics.”
Models repetitive elements, neoantigens and tumor evolution with statistical physics and information theory. Bridges MSK Computational Oncology with the Parker Institute for Cancer Immunotherapy.
124 papers since 2024
›
RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer
Nature, 2025
IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer
Nature, 2025
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer
Covers pathology, laboratory medicine, molecular diagnostics and clinical bioinformatics, including clinical next-generation sequencing. Customizes patients’ treatments with other specialists based on individual diagnoses.
Reanalyzes DNA-sequencing libraries and develops PERFF-seq technology for rare-cell profiling alongside scRNA-seq. Studies human viromes, cancer immune cells and protein binders for cancer therapy.
146 papers since 2024
›
FOXO1 is a master regulator of memory programming in CAR T cells
Nature, 2024
Deciphering the impact of genomic variation on function
Nature, 2024
Distinct epigenomic landscapes underlie tissue-specific memory T cell differentiation
Combines Perturb-seq, single-cell CRISPR screens and computational modeling in fibroblasts. Uses them to engineer cell state for cell therapy and disease modeling.
8 papers since 2024
›
Comprehensive transcription factor perturbations recapitulate fibroblast transcriptional states
Nature Genetics, 2025
Multiome Perturb-seq unlocks scalable discovery of integrated perturbation effects on the transcriptome and epigenome
Studies inherited cancer risk using germline genome sequencing, MSK IMPACT, CRISPR screens and organoids. Translates germline cancer genetics to the clinic.
67 papers since 2024
›
Germline genetic variation impacts clonal hematopoiesis landscape and progression to malignancy
Nature Genetics, 2025
Assessing the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases
Nature Communications, 2025
Validation of a clinical breast cancer risk assessment tool combining a polygenic score for all ancestries with traditional risk factors